Growth in patients with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency.
BACKGROUND
One important goal in the management of children with classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency is to achieve normal growth. Reviewing available data published over the last few years on growth and height outcomes in CAH patients, it becomes evident that an acceptable height can be achieved by many CAH patients. However, linear growth and final adult height may be stunted in some patients due to factors related to the timing of diagnosis, the age at therapy onset, the start of therapy, the adequacy of metabolic control, the quality of therapy, patient compliance and the experience of the treating physician. In children with CAH who have a poor height prognosis, additional treatment options should be considered.


CONCLUSIONS
Treatment of children with CAH requires individualized approaches to prevent long-term growth failure.
Dörr
Helmuth G
HG
Division of Pediatric Endocrinology, University Hospital for Children and Adolescents, Erlangen, Germany. helmuth-guenther.doerr@kinder.imed.uni-erlangen.de
D000312:Adrenal Hyperplasia, Congenital / Q000188:drug therapy* / Q000503:physiopathology*; D001827:Body Height / Q000187:drug effects; D002657:Child Development; D002675:Child, Preschool; D004334:Drug Administration Schedule; D006128:Growth / Q000187:drug effects; D006801:Humans; D013256:Steroids / Q000008:administration & dosage / Q000627:therapeutic use*; D035703:Therapies, Investigational
D013256:Steroids